Thryv Therapeutics Announces Four Abstracts Accepted for AHA 2024 Annual Scientific Sessions
Montreal, Quebec – October 23, 2024 – Thryv Therapeutics Inc., a biotechnology company pioneering precision treatments for cardiovascular conditions, including congenital Long QT Syndrome, atrial fibrillation and heart failure, is proud to announce the acceptance of four abstracts for presentation at the prestigious American Heart Association’s (AHA) 2024 Annual Scientific Sessions. The event, which brings together global experts to exchange the latest advancements in cardiovascular science, clinical care, and research, will take place from November 16 - 18, 2024, at the McCormick Place Convention Center in Chicago, Illinois.
Thryv Therapeutics is honored to contribute to this important dialogue with its recent research.
Presentation Details
Poster Presentation Title 1: Serum Glucocorticoid Regulated Kinase 1 (SGK-1) Inhibitor Reduced Hypertension in a Salt-Sensitive Hypertension Model of Heart Failure with Preserved Ejection Fraction
Presentation Date: Saturday, November 16, 2024
Presentation Time: 2:00-3:00 p.m. CST
Location: Zone 2
Poster Presentation Title 2: Serum and Glucocorticoid Regulated Kinase 1 (SGK1) Inhibition Induces Anti-Fibrotic and Anti-Inflammatory Responses: Relevance to Cardiac Fibrosis
Presentation Date: Monday, November 18, 2024
Presentation Time: 1:30-2:30 p.m. CST
Location: Zone 1, Science & Technology Hall
Poster Presentation Title 3: SGK1 inhibition attenuated left ventricular thickening and diastolic dysfunction in a mouse model of Heart Failure with Preserved Ejection Fraction
Presentation Date: Saturday, November 16, 2024
Presentation Time: 2:00-3:00 pm CST
Location: Zone 2
Poster Presentation Title 4: SGK1 inhibition shortens action potential duration in LQT3 mice and LQT2 rabbits via inhibition of late sodium current
Presentation Date: Sunday, November 17, 2024
Presentation Time: 3:15-3:20 p.m. CST
Location: Zone 4, Moderated Digital Poster 23
To schedule a meeting with a representative from Thryv at the AHA Annual Scientific Sessions, please email: admin@thryvtrx.com.
For more information about the AHA Annual Scientific Sessions, please visit: ahascientificsessions.org
About Thryv Therapeutics Inc.
Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop highly selective SGK1 inhibitors to treat Long QT Syndrome, atrial fibrillation and heart failure, with potent and selective inhibitors of serum glucocorticoid inducible kinase. For more information, please visit www.thryvtrx.ca.
Media Inquiries
brittany@thryvtrx.com | 514 973 0915
